Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Mutations in the transcriptional repressor REST predispose to Wilms tumor

A Corrigendum to this article was published on 29 March 2016

This article has been updated

Abstract

Wilms tumor is the most common childhood renal cancer1. To identify mutations that predispose to Wilms tumor, we are conducting exome sequencing studies. Here we describe 11 different inactivating mutations in the REST gene (encoding RE1-silencing transcription factor) in four familial Wilms tumor pedigrees and nine non-familial cases. Notably, no similar mutations were identified in the ICR1000 control series2 (13/558 versus 0/993; P < 0.0001) or in the ExAC series (13/558 versus 0/61,312; P < 0.0001). We identified a second mutational event in two tumors, suggesting that REST may act as a tumor-suppressor gene in Wilms tumor pathogenesis. REST is a zinc-finger transcription factor that functions in cellular differentiation and embryonic development3,4. Notably, ten of 11 mutations clustered within the portion of REST encoding the DNA-binding domain, and functional analyses showed that these mutations compromise REST transcriptional repression. These data establish REST as a Wilms tumor predisposition gene accounting for 2% of Wilms tumor.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Figure 1: Position and tumor impact of REST mutations in Wilms tumor cases.
Figure 2: Mutations identified in Wilms tumor cases result in deficiency in transcriptional repression.

Change history

  • 08 February 2016

    In the version of this article initially published, the authors failed to acknowledge funding from the NIHR Biomedical Research Centre at Great Ormond Street Hospital for Children NHS Foundation Trust and University College London to Neil Sebire. The error has been corrected in the HTML and PDF versions of the article.

References

  1. Hohenstein, P., Pritchard-Jones, K. & Charlton, J. The yin and yang of kidney development and Wilms' tumors. Genes Dev. 29, 467–482 (2015).

    Article  CAS  Google Scholar 

  2. Ruark, E. et al. The ICR1000 UK exome series: a resource of gene variation in an outbred population. F1000 Res. 4, 883 (2015).

    Article  Google Scholar 

  3. Bithell, A. REST: transcriptional and epigenetic regulator. Epigenomics 3, 47–58 (2011).

    Article  CAS  Google Scholar 

  4. Ooi, L. & Wood, I.C. Chromatin crosstalk in development and disease: lessons from REST. Nat. Rev. Genet. 8, 544–554 (2007).

    Article  CAS  Google Scholar 

  5. Scott, R.H., Stiller, C.A., Walker, L. & Rahman, N. Syndromes and constitutional chromosomal abnormalities associated with Wilms tumour. J. Med. Genet. 43, 705–715 (2006).

    Article  CAS  Google Scholar 

  6. Hanks, S. et al. Germline mutations in the PAF1 complex gene CTR9 predispose to Wilms tumour. Nat. Commun. 5, 4398 (2014).

    Article  CAS  Google Scholar 

  7. Rahman, N. et al. Evidence for a familial Wilms' tumour gene (FWT1) on chromosome 17q12-q21. Nat. Genet. 13, 461–463 (1996).

    Article  CAS  Google Scholar 

  8. McDonald, J.M. et al. Linkage of familial Wilms' tumor predisposition to chromosome 19 and a two-locus model for the etiology of familial tumors. Cancer Res. 58, 1387–1390 (1998).

    CAS  PubMed  Google Scholar 

  9. Rapley, E.A. et al. Evidence for susceptibility genes to familial Wilms tumour in addition to WT1, FWT1 and FWT2. Br. J. Cancer 83, 177–183 (2000).

    Article  CAS  Google Scholar 

  10. Ruark, E. et al. Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer. Nature 493, 406–410 (2013).

    Article  CAS  Google Scholar 

  11. Forbes, S.A. et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 39, D945–D950 (2011).

    Article  CAS  Google Scholar 

  12. Lu, T. et al. REST and stress resistance in ageing and Alzheimer's disease. Nature 507, 448–454 (2014).

    Article  CAS  Google Scholar 

  13. Buckley, N.J., Johnson, R., Zuccato, C., Bithell, A. & Cattaneo, E. The role of REST in transcriptional and epigenetic dysregulation in Huntington's disease. Neurobiol. Dis. 39, 28–39 (2010).

    Article  CAS  Google Scholar 

  14. Canzonetta, C. et al. DYRK1A-dosage imbalance perturbs NRSF/REST levels, deregulating pluripotency and embryonic stem cell fate in Down syndrome. Am. J. Hum. Genet. 83, 388–400 (2008).

    Article  CAS  Google Scholar 

  15. Karlin, K.L. et al. The oncogenic STP axis promotes triple-negative breast cancer via degradation of the REST tumor suppressor. Cell Rep. 9, 1318–1332 (2014).

    Article  CAS  Google Scholar 

  16. Gurrola-Diaz, C., Lacroix, J., Dihlmann, S., Becker, C.M. & von Knebel Doeberitz, M. Reduced expression of the neuron restrictive silencer factor permits transcription of glycine receptor α1 subunit in small-cell lung cancer cells. Oncogene 22, 5636–5645 (2003).

    Article  CAS  Google Scholar 

  17. Kreisler, A. et al. Regulation of the NRSF/REST gene by methylation and CREB affects the cellular phenotype of small-cell lung cancer. Oncogene 29, 5828–5838 (2010).

    Article  CAS  Google Scholar 

  18. Tawadros, T. et al. IB1/JIP-1 controls JNK activation and increased during prostatic LNCaP cells neuroendocrine differentiation. Cell. Signal. 17, 929–939 (2005).

    Article  CAS  Google Scholar 

  19. Ballas, N., Grunseich, C., Lu, D.D., Speh, J.C. & Mandel, G. REST and its corepressors mediate plasticity of neuronal gene chromatin throughout neurogenesis. Cell 121, 645–657 (2005).

    Article  CAS  Google Scholar 

  20. Little, S.E. et al. Frequency and heritability of WT1 mutations in nonsyndromic Wilms' tumor patients: a UK Children's Cancer Study Group Study. J. Clin. Oncol. 22, 4140–4146 (2004).

    Article  CAS  Google Scholar 

  21. Scott, R.H. et al. Surveillance for Wilms tumour in at-risk children: pragmatic recommendations for best practice. Arch. Dis. Child. 91, 995–999 (2006).

    Article  CAS  Google Scholar 

  22. Lunter, G. & Goodson, M. Stampy: a statistical algorithm for sensitive and fast mapping of Illumina sequence reads. Genome Res. 21, 936–939 (2011).

    Article  CAS  Google Scholar 

  23. Rimmer, A. et al. Integrating mapping-, assembly- and haplotype-based approaches for calling variants in clinical sequencing applications. Nat. Genet. 46, 912–918 (2014).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank the families for their participation in our research and the physicians and nurses who recruited them. Samples were collected through the Factors Associated with Childhood Tumours (FACT) study, which is a Children's Cancer and Leukaemia (CCLG) Study (UK National Research Ethics Service reference 05/MRE02/17). The individuals who recruited patients with Wilms tumor for this study are listed in the Supplementary Note. We thank M. Warren-Perry and J. Bull for assistance in recruitment and A. Strydom for assistance in preparing the manuscript. We acknowledge NHS funding to the Royal Marsden/Institute of Cancer Research National Institute for Health Research (NIHR) Biomedical Research Centre. The authors acknowledge joint participation by the Adrienne Helis Melvin Medical Research Foundation through its direct engagement in the continuous active conduct of medical research in conjunction with Baylor College of Medicine for cancer research. T.F.W. and K.L.K. were supported by the Cancer Prevention Research Institute of Texas (CPRIT; RP120583), the US National Institutes of Health (1R01CA178039-01) and the US Department of Defense Breast Cancer Research Program (BC120604). This research was supported by the Wellcome Trust (088804/Z/09/Z) and the Rosetrees Trust. This research was supported by the NIHR Biomedical Research Centre at Great Ormond Street Hospital for Children NHS Foundation Trust and University College London (to N.S.).

Author information

Authors and Affiliations

Authors

Contributions

N.R. designed and oversaw the study. S.S.M., S.H., E.R.P., Anthony Renwick, E. Ramsay and S.S. performed the molecular analyses. E. Ruark, A.E., S.Y., C.A.S. and Alexander Renwick performed bioinformatics analyses. J.B., M.C., J.G., J.H., J.K., G.L., T.M., E.S. and C.S. provided samples and data, coordinated by A.Z. K.L.K. and T.F.W. undertook functional analyses. N.S. undertook pathology review. S.S.M., S.H., K.L.K., T.F.W. and N.R. wrote the manuscript with input from the other authors.

Corresponding author

Correspondence to Nazneen Rahman.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Integrated supplementary information

Supplementary Figure 1 Sanger sequencing chromatograms of germline REST mutations in Wilms tumor cases and corresponding wild-type sequences from a control.

Supplementary Figure 2 Pedigrees of Wilms tumor cases with germline REST mutations.

Individuals with Wilms tumor (WT) are represented by shaded symbols, with age at diagnosis in years given below. Circles depict females, and squares depict males.

Supplementary Figure 3 REST mutants identified in Wilms tumor cases are deficient in transcriptional repression relative to the normalizing control GAPDH.

(a) Expression of REST target genes was assessed in REST-deficient breast cancer cells (SUM149) expressing the indicated cDNAs by qRT-PCR. Relative expression of the REST target complexin 1 is not shown, as it is not expressed in the SUM149 cell line. (b) Expression of REST target genes was assessed in REST-deficient colon cancer cells (SW1417) expressing the indicated cDNAs by qRT-PCR. GFP, green fluorescent protein control; WT, wild-type REST. REST mutations within the DNA-binding domain and/or truncating mutations are shown in bold.

Supplementary information

Supplementary Text and Figures

Supplementary Figures 1–3, Supplementary Tables 1–3 and Supplementary Note. (PDF 2507 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Mahamdallie, S., Hanks, S., Karlin, K. et al. Mutations in the transcriptional repressor REST predispose to Wilms tumor. Nat Genet 47, 1471–1474 (2015). https://doi.org/10.1038/ng.3440

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ng.3440

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing